Re:Unconventional Case Study of Neoadjuvant Oncolytic Viroth...
by markus92 on Monday September 09, 2024 @04:48AM
(#41486617)
The really interesting part of this study (besides the obvious self-experimentation) is that she underwent subtype conversion from TN to HER2+ tumor and thus could use Trastuzumab.
[ Parent
| on HN ]
Re:Unconventional Case Study of Neoadjuvant Oncolytic Viroth...
by CipherThrowaway on Monday September 09, 2024 @07:48AM
(#41487607)
The development of PD-L1 expression was also interesting.